Randomized Multi-Institutional Phase III Trial of BEP and High Dose Chemotherapy Versus BEP Alone in Previously Untreated Patients With Poor and Intermediate Risk Germ Cell Tumors

Poor Risk Nonseminomatous Germ Cell Tumors: Testis or retroperitoneal primary site: 1) without visceral metastasis AND poor markers (AFP, LDH or HCG) OR 2) with visceral metastasis OR 3) Mediastinal NSGCT primary site. Confirmation of germ cell histology, no prior chemo, prior RT OK if evidence of progressive disease documented and toxicities abated, must have measurable or evaluable disease.